Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438559 | 0.75 | — | — | |
| SCHEMBL13772993 | 0.71 | — | — | |
| SCHEMBL301586 | 0.70 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1 | |
| SCHEMBL11301061 | 0.67 | ALDH1A1 (0.33) | ALDH1A1TSHRTDP1 | |
| SCHEMBL25097660 | 0.64 | — | — | |
| SCHEMBL3729759 | 0.64 | TSHR (0.31) | ALDH1A1TSHRTDP1 | |
| SCHEMBL453798 | 0.64 | TDP1 (0.31) | ALDH1A1TSHRTDP1 | |
| SCHEMBL3902544 | 0.64 | TSHR (0.31) | ALDH1A1TSHRTDP1 | |
| SCHEMBL211658 | 0.64 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1 | |
| SCHEMBL2216329 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964654-A | Synthesis method of arginate-ammonium phosphonate | 南京盛德创赢生物科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2017082924-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | ALDH1A1 1718/4885TSHR 4874/4885TDP1 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.